New weight loss pill could replace needles: early human testing begins

NCT ID NCT07388667

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests MK-4082, a new weight loss pill, in 120 healthy overweight or obese adults. Unlike current injectable weight loss drugs, this medicine is taken as a pill. The main goal is to check safety and how the body processes different doses, not yet to measure weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-4082 (oral tablet)
What this could lead to: If this pill is safe and works, it could lead to a new weight loss medicine taken as a pill instead of an injection.
What could go wrong: This is a very early Phase 1 study in healthy people, not yet testing weight loss. The drug may not work or could have side effects. Many early drugs fail.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Anaheim Clinical Trials ( Site 0005)

Anaheim, California, 92801, United States
Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0004)

Springfield, Missouri, 65802, United States
Hassman Research Institute Marlton Site ( Site 0006)

Marlton, New Jersey, 08053, United States
ProSciento Inc. ( Site 0002)

Chula Vista, California, 91911, United States
QPS-MRA, LLC ( Site 0003)

South Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.